163768-51-2 Usage
Description
(S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-hydroxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate, also known as tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-hydroxy-2-methyl-3-oxo-1-propyl)pyrrolidine-1-carboxylate, is a pyrrolidine derivative with a tert-butyl ester group and a hydroxy-methyl-oxo-propyl substituent. This complex organic compound serves as a vital building block in the synthesis of pharmaceutical drugs and organic compounds, contributing significantly to drug discovery and development.
Uses
Used in Pharmaceutical Industry:
(S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-hydroxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceutical drugs. Its unique structure allows for the creation of active ingredients in medications, making it an essential component in drug development.
Used in Organic Chemistry:
In the field of organic chemistry, (S)-tert-butyl 2-((1R,2R)-3-(benzyloxy)-1-hydroxy-2-methyl-3-oxopropyl)pyrrolidine-1-carboxylate is utilized as a versatile building block for the synthesis of a wide range of organic compounds. Its structural diversity and reactivity make it a valuable asset in the development of new chemical entities with potential applications in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 163768-51-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,6,3,7,6 and 8 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 163768-51:
(8*1)+(7*6)+(6*3)+(5*7)+(4*6)+(3*8)+(2*5)+(1*1)=162
162 % 10 = 2
So 163768-51-2 is a valid CAS Registry Number.
163768-51-2Relevant articles and documents
Synthesis and antitumor activity of novel dolastatin 10 analogs
Miyazaki,Kobayashi,Natsume,Gondo,Mikami,Sakakibara,Tsukagoshi
, p. 1706 - 1718 (2007/10/03)
Dolastatin 10 (1) is a potent antineoplastic pentapeptide. Novel dolastatin 10 analogs each modified at one of the constituent amino acid derivatives, were synthesized and their antitumor activity was evaluated against P388 leukemia in mice. The structural requirements for antitumor activity are discussed. Some of the analogs, 31c, 35c, 38b, and 50c showed excellent activity in vivo. Highly active 50c, which lacks the thiazole group of 1, was selected for further development as an antitumor agent.